Risk Management Assessments Will Be Part Of Advisory Committees - FDA

Risk management and other postmarketing safety considerations should be discussed during pre-approval advisory committee meetings, CDER participants maintained in a June 22 satellite workshop on minimizing pharmaceutical contributions to medical errors.